Patents Assigned to Proyecto de Biomedicina CIMA, S.L.
-
Patent number: 10545150Abstract: The invention provides a method of diagnosis and/or prognosis of lung cancer, the method comprising the steps of: (a) determining the level of a C4 activation fragment in a test sample, and (b) comparing the level of the test sample with the level of a C4 activation fragment detected in a control sample, wherein if the level of C4 activation fragment is higher than the level in a reference control, it is indicative that the subject suffers lung cancer or has a bad prognosis. The present invention further provides methods for determining the risk of suffering from lung cancer as well as for deciding whether to initiate a medical regimen and to determine the efficacy of said medical regimen, based on the determination of a C4 activation fragment. C4 activation fragment, used as marker, confers high sensitivity and specificity to the methods object of the invention.Type: GrantFiled: March 20, 2013Date of Patent: January 28, 2020Assignee: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Daniel Ajona Martínez-Polo, Leticia Corrales Pecino, Luis Montuenga Badía, María José Pajares Villandiego, Rubén Pío Osés
-
Patent number: 9440989Abstract: It relates to spirocyclic compounds of formula (I), or pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the compounds of formula (I) or of their pharmaceutically or veterinary acceptable salts, wherein A and B form a spirocyclic ring system wherein the spiro atom connecting A and B is a carbon atom and wherein A is a known 3- to 8-membered carbocyclic or heterocyclic monocyclic ring or a known 6- to 18-membered carbocyclic or heterocyclic polycyclic ring system; B is a known 4- to 7-membered carbocyclic or heterocyclic monocyclic ring; C is phenyl or a known 5- to 6-membered heteroaromatic ring; and R1-R7 are as defined herein. It also relates to a process for their preparation, as well as to the intermediates used in this process; to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular as antifibrinolytic and antihemorragic agents.Type: GrantFiled: July 17, 2013Date of Patent: September 13, 2016Assignee: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Josune Orbe Lopategui, Julen Oyarzabal Santamarina, José Antonio Páramo Fernández, José Antonio Rodriguez Garcia
-
Publication number: 20160074475Abstract: The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the Apo A molecule.Type: ApplicationFiled: November 20, 2015Publication date: March 17, 2016Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Jesús María PRIETO VALTUEÑA, Pedro BERRAONDO LÓPEZ, Jessica FIORAVANTI
-
Patent number: 9155783Abstract: This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.Type: GrantFiled: June 13, 2006Date of Patent: October 13, 2015Assignee: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Claude Leclerc, Juan Jose Lasarte Sagastibelza, Marta Gorraiz Ayala, Jesus Prieto Valtuena
-
Patent number: 8697665Abstract: The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3.Type: GrantFiled: September 29, 2009Date of Patent: April 15, 2014Assignees: Proyecto de Biomedicina CIMA S.L., Uniqure Biopharma B.V.Inventors: Antonio Fontanellas Romá, Gloria González Aseguinolaza, Maria Sol Rodriguez Pena, Maria Astrid Pañeda Rodriguez, Jaap Twisk, Jesús Maria Prieto Valtueña, Harald Petry, Sander Jan Hendrik Van Deventer
-
Publication number: 20140056943Abstract: The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus.Type: ApplicationFiled: September 27, 2013Publication date: February 27, 2014Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Aintzane ZABALETA AZPIROZ, Francisco BORRAS CUESTA, Jesus PRIETO VALTUENA, Pablo SAROBE UGARRIZA, Juan Jose LASARTE SAGASTIBELZA
-
Patent number: 8541370Abstract: The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders.Type: GrantFiled: August 23, 2010Date of Patent: September 24, 2013Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Josune Orbe Lopategui, Jose Antonio Rodriguez Garcia, Jose Antonio Paramo Fernandez, Rosario Serrano Vargas
-
Patent number: 8524860Abstract: The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15, wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases.Type: GrantFiled: November 14, 2008Date of Patent: September 3, 2013Assignee: Proyecto de Biomedicina CIMA, S.L.Inventors: Inés Noelia Casares Lagar, Francisco Borrás Cuesta, Pablo Sarobe Ugarriza, Jesús Maria Prieto Valtueña, Juan José Lasarte Sagastibelza
-
Publication number: 20130130225Abstract: The present invention relates to a cold organ preservation composition for transplantation comprising a cold organ preservation solution and cardiotrophin-1 or a functionally equivalent variant thereof. The invention also relates to methods and kits for the preparation of said composition, the uses thereof for the cold organ protection and/or preservation for transplantation (particularly for kidney, lung and heart) and also to the cold preservation methods and cold-preserved isolated organs by these methods.Type: ApplicationFiled: May 24, 2011Publication date: May 23, 2013Applicants: PROYECTO DE BIOMEDICINA CIMA, S.L., DIGNA BIOTECH, S.L.Inventors: Haisul C.Y. Chang, Victor Fernández Gallego, María Iñiguez Martínez, Jose Miguel Lopez Novoa, Jesús María Prieto Valtueña, Juan Ruiz Echeverría
-
Publication number: 20130064790Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: ApplicationFiled: March 8, 2012Publication date: March 14, 2013Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Lorea MANTEROLA CAREAGA, Inés Noelia CASARES LAGAR, Nancy Díaz-Valdés Farray, Javier DOTOR DE LAS HERRERÍAS, Juan José LASARTE SAGASTIBELZA, Pablo SAROBE UGARRIZA, Jesús PRIETO VALTUEÑA, Francisco BORRÁS CUESTA
-
Publication number: 20120315256Abstract: The invention refers to the use of transforming growth factor-beta 1 (TGF-?1) inhibitor peptides or polynucleotides encoding said peptides for the prevention and/or treatment of corneal fibrosis and/or corneal haze.Type: ApplicationFiled: February 21, 2011Publication date: December 13, 2012Applicants: DIGNA BIOTECH, S.I., PROYECTO DE BIOMEDICINA CIMA S.L.Inventors: Javier Dotor De Las Herrerias, Miguel Jose Maldonado Lopez
-
Publication number: 20120308517Abstract: The present invention relates to the use of compositions comprising a type III interferon and oncostatin M and to the use of said compositions for the treatment and prevention of infectious and neoplastic diseases.Type: ApplicationFiled: February 7, 2011Publication date: December 6, 2012Applicants: DIGNA BIOTECH, S.L., PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Rafael Aldabe Arregui, Iranzu Gonzalez De La Tajada, Maria Esther Larrea Leoz, Jesus Maria Prieto Valtuena
-
Publication number: 20120237535Abstract: The invention relates to immunogenic conjugates comprising an immunogenic region of human papilloma virus E7 protein and the fibronectin EDA region, as well to compositions comprising said conjugates and to dendritic cells obtained by stimulation with said conjugates and compositions. Moreover, the invention relates to methods for the treatment of diseases caused by the human papilloma virus (HPV) using said conjugates, compositions and dendritic cells.Type: ApplicationFiled: September 10, 2010Publication date: September 20, 2012Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Pedro Berraondo-Lopez, Juan Jose Lasarte Sagastibelza, Christina Mansilla Puerta, Jesus Maria Prieto Valtuena, Pablo Sarobe Ugarriza
-
Patent number: 8257701Abstract: The present invention concerns the use of a neutralizing antibody for matrix metalloproteinase-10 (MMP-10) in the preparation of a medicine useful for anti-fibrinolytic treatment, and for hemorrhages and hemorrhagic complications of various etiologies.Type: GrantFiled: June 26, 2008Date of Patent: September 4, 2012Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Josune Orbe Lopategui, Jóse Antonio Rodríguez García, José Antonio Páramo Fernández, Rosario Serrano Vargas
-
Patent number: 8236778Abstract: The present invention relates to combinations of 5?-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5?-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and/or treatment of multiple sclerosis.Type: GrantFiled: March 18, 2009Date of Patent: August 7, 2012Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Matías Antonio Ávila Zaragozá, Fernando José Corrales Izquierdo, Begoña Fernández Díez, Beatriz Moreno Bruna, Pablo Villoslada Díaz
-
Publication number: 20120093775Abstract: The invention provides a method for the treatment of cirrhosis and liver fibrosis by the use or viral vectors containing the gene encoding IGF-I. The invention discloses both parvoviral vectors and SV40-based vectors as well uses thereof for the treatment of cirrhosis and gene therapy and methods for the preparation of said viral vectors.Type: ApplicationFiled: March 26, 2010Publication date: April 19, 2012Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Maria Purificaion Fortes Alonso, Jesús Maria Prieto Valtueña, Luciano Matías Sobrevals, Harald Petry, Eric Jacobus Hubertus Timmermans
-
Publication number: 20120083464Abstract: The present invention relates to the use of MTA, its pharmaceutically acceptable salts and/or prodrugs thereof as active ingredient in the manufacture of a medicament for the prevention or treatment of nerve cell death or damage, a neuroprotective medicament, a medicament for the regeneration of nerve cells, and a medicament for the prevention or treatment of a neurological or psychiatric disease. The present invention also relates to a method of prevention or treatment of nerve cell death or damage, a method of neuroprotection, a method of regenerating nerve cells and a method of prevention or treatment of a neurological or psychiatric disease.Type: ApplicationFiled: June 7, 2010Publication date: April 5, 2012Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventor: Pablo Villoslada Diaz
-
Patent number: 8148334Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: GrantFiled: March 27, 2008Date of Patent: April 3, 2012Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Lorea Manterola Careaga, Inés Noelia Casares Lagar, Nancy Díaz-Valdés Farray, Javier Dotor de las Herrerías, Juan José Lasarte Sagastibelza, Pablo Sarobe Ugarriza, Jesús Prieto Valtueñ, Francisco Borrás Cuesta
-
Publication number: 20110293557Abstract: The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the ApoA molecule.Type: ApplicationFiled: June 12, 2009Publication date: December 1, 2011Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Jesús Maria Prieto Valtueña, Pedro Berraondo López, Jessica Fioravanti
-
Publication number: 20110293562Abstract: The invention is related to the use of cardiotrophin-1 (CT-1) for the treatment of obesity and associated disorders: hyperglycaemias, insulin resistance, development of type 2 diabetes and dyslipemias and given its anorexigenic role, fat oxidation stimulant, hypoglycaemic, sensitizing agent of the action of insulin on a skeletal muscle level and inhibitor of the intestinal transport of glucose by enterocytes.Type: ApplicationFiled: February 10, 2010Publication date: December 1, 2011Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Jesus Maria Prieto Valtuena, Matilde Bustos De Abajo, Maria Jesus Moreno Aliaga